chrisvoncsefalvay/vaers-outcomes huggingface dataset:
She started having shortness of breath, bloody noses and a lot of mucus around her heart and lungs. She did not have any issues like this prior to the vaccinations. They told us she had lung disease which was quite a surprise and not expected. She had bone issues, but not lung issues ever. Or heart issues, her heart was strong and it took a long time for her heart to stop beating!
Lower medial thigh swelling and erythema hot to touch with heavy central induration, 14cm x 9cm.  Placed on Keflex by mouth.
Other than the normal symptoms of chills, body aches, feeling run down....the day after I had the second dose, I experienced a fainting episode and collapsed on the floor.
This spontaneous report received from a nurse refers to a patient of unknown age. Information on pertinent medical history and concurrent condition was not provided. Information on pertinent medical history and concurrent condition was not provided. On an unknown date, the patient was vaccinated with VARIVAX lot # M038856 for prophylaxis. The Nurse reported that the vaccine administered was improperly stored. No adverse event reported. The outcome of incorrect product storage and no adverse event was unknown. Lot M038856 was stored in the range of -14°C to-10°C for 483 hours and in the range of -9°C to 8°C for 28 hours. No previous temperature excursion The call was not because of a "data logger". Additional information has been requested.
bloody sinus drainage; Nose bleed; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 20 year-old patient received bnt162b2 (BNT162B2), administered in arm left, administration date 22Sep2021 (Batch/Lot number: unknown) at the age of 20 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "ADHD" (unspecified if ongoing); "Asthma" (unspecified if ongoing); "Scoliosis (corrected)" (unspecified if ongoing); "SMA" (unspecified if ongoing); "hypoglycemia" (unspecified if ongoing); "Anemia" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (Dose 1, Arm Right), administration date: 01Sep2021, for COVID-19 immunization. The following information was reported: EPISTAXIS (non-serious) with onset 22Sep2021 21:30, outcome "recovering", described as "bloody sinus drainage"; EPISTAXIS (non-serious) with onset 22Sep2021 21:30, outcome "recovering", described as "Nose bleed". Therapeutic measures were not taken as a result of epistaxis, epistaxis.  Additional Information: Prior to vaccination, patient was not diagnosed with Covid-19. Since the vaccination, patient has not been tested for Covid-19. Patient did not receive any other vaccines within 4 weeks prior to the Covid vaccine. Facility where the most recent COVID-19 vaccine administered was Pharmacy or Drug Store. Other medications the patient received within 2 weeks of vaccination: Pristiq 100mg, vyvanse 40mg, Nikki, probiotics.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Sometime in Dec, I noticed my heart rate would increase drastically then drop which started to cause dizziness. I began to feel nerve tingling in my left arm. This continued through January and Feb 2022. In Feb, I experienced a severe migraines and went to the ER.
EPIGASTRIC PAIN, NAUSEA, COLICS ON A MONTLY BASIS FOR THE NEXT 12 MONTHS AFTER VACCINE DOCTORS INITIALLY MISDIAGNOSE PATIENT AND SEND PATIENT HOME AFTER INITIAL ER VISIT 2 MONTHS AFTER VACCINATION. FOR THE NEXT 12 MONTHS AND AS STATED BEFORE THE SYMPTOMS AND PAIN INCREASED ON A MONTHLY BASIS  CONSECUENTLY , PATIENT WAS ADMITTED IN THE ER AGAIN, LATER HOSPITALIZED AND HAVE GALLDBLADDER REMOVAL ON AN EMERGENCY BASIS.
myalgia; chills; headache; fatigue; Loss of appetite; This is a spontaneous report from a non-contactable physician. A 44-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EH9899), via an unspecified route of administration on 21Dec2020 14:30 in left arm at single dose for COVID-19 immunization. Medical history included COVID-19 from an unknown date and unknown if ongoing. Concomitant medication included omeprazole. After vaccination, 12-15 hours later, the patient pronounced myalgia joined 18 hours later with chills, headache, fatigue and loss of appetite. The patient experienced myalgia on 22Dec2020 05:00; chills, headache, loss of appetite and fatigue on 22Dec2020. Treatment such as acetaminophen and rest was given to patient for the events. The facility where the most recent COVID-19 vaccine was administered was in the hospital. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. The patient had no allergies to medications, food, or other products. The events were considered non serious as it did not results in death, was not life threatening, did not cause/prolonged hospitalization, was not disabling/Incapacitating and had no congenital anomaly/birth defect. The outcome of the events was not recovered.  No follow up attempts are possible. No further information is expected.
pt achy, hives, rt arm tender, erythema, firm induration; no rash, no inflamed nodes; no n&v; temp not taken erythema papules bilateral (breast);
increase in hear rate, went to ER, admitted to hospital; shortness of breath, admitted to hospital for a few days; dizziness, admitted to hospital; fluid retention, admitted to hospital; This case was reported by a consumer via call center representative and described the occurrence of heart rate increased in a 70-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 10th June 2022, the patient received the 1st dose of Shingrix. In June 2022, 4 days after receiving Shingrix, the patient experienced heart rate increased (serious criteria hospitalization), shortness of breath (serious criteria hospitalization), dizziness (serious criteria hospitalization) and fluid retention (serious criteria hospitalization). On an unknown date, the outcome of the heart rate increased, shortness of breath, dizziness and fluid retention were recovered/resolved.   It was unknown if the reporter considered the heart rate increased, shortness of breath, dizziness and fluid retention to be related to Shingrix.     Additional Information: GSK Receipt Date: 05-Aug-2022 Reporter's Comments: The patient self-reported this case The patient wanted to know if side effects could happen 3 to 4 days after receiving Shingrix vaccine. The patient stated that, 4 days after Shingrix dose 1 she experienced an increase in her hear rate, shortness of breath, dizziness and fluid retention. She had to go to emergency room and admitted to hospital for a few days. Her symptoms subsided but she asked if it was safe to get dose 2 of Shingrix vaccine. The reporter consent to follow up with HCP and herself.
Metal taste back of mouth; Burning Heat; pain radiating down arms with nerve pulling/moving sensation to tips of fingers; pain radiating down arms with nerve pulling/moving sensation to tips of fingers; This is a spontaneous report from a contactable other healthcare professional (patient). A 43-years-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE), lot number: ejko85, intramuscular on 22-DEC-2020 11:45 (at the age of 43-years-old) as a single dose in the left arm for COVID-19 immunization.  Medical history had known allergies to latex. The patient's concomitant medications were not reported. The patient was not pregnant at the time of vaccination.  Prior to vaccination, the patient was not diagnosed with COVID-19. On 22Dec2020 01:15AM, the patient experienced metal taste back of mouth, burning heat, pain radiating down arms with nerve pulling/moving sensation to tips of fingers. The metal taste back of mouth, burning heat, pain radiating down arms with nerve pulling/moving sensation to tips of fingers did not result in death, was not life-threatening, did not cause/prolonged hospitalization, was not disabling/incapacitating and did not cause congenital anomaly/birth defect. No treatment was received for the events metal taste back of mouth, burning heat, pain radiating down arms with nerve pulling/moving sensation to tips of fingers.  Outcome of the events metal taste back of mouth, burning heat, pain radiating down arms with nerve pulling/moving sensation to tips of fingers. Since the vaccination, the patient has not been tested for COVID-19.  Information on the lot/batch number has been requested.
Symptoms initially began 3 weeks after COVID-19 dose #1. "Started with rash on back of neck at hairline, described as bumpy, itchy and red lacey looking at edges, described as splotchy with progression to shoulders, and down back. Red spots eventually turned to brown color like a suntan". Symptoms escalated by evening following dose #2, with painful spots and severe itching. Feels worst has now passed. Described feeling of "itch about to happen".  Has appt pending with dermatologist 6/8/21. PCP currently closed until July and referred to Public Health clinic to report. At time of report, patient was encouraged to seek evaluation/treatment at walk-in clinic in interim while awaiting dermatology appt.
she received when got vaccine such as chills, a headache; She says she is also experiencing dizzy spells which are not listed.; Tiredness; Aches; She says her left arm was painful when she got the vaccine; it is still sore now but it is not as painful; she received when got vaccine such as chills, a headache; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 33 year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 08May2021 11:30 (Lot number: EW0173) at the age of 33 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "anxiety" (unspecified if ongoing), notes: she just takes anxiety and depression medications but she would rather leave them out.; "depression" (unspecified if ongoing), notes: she just takes anxiety and depression medications but she would rather leave them out. The patient took concomitant medications. Vaccination history included: Bnt162b2 (Dose 1, lot number: EW0164, Expire Date: Unknown, Time: 2:30pm, anatomical location: left arm), administration date: 18Apr2021, for COVID-19 immunisation, reaction(s): "painful arm and tiredness", "painful arm and tiredness"; Flu vaccine (she had a reaction to the flu vaccine years ago and her reaction was full on flu for about 2 weeks.), for immunisation, reaction(s): "she got the full on flu". The following information was reported: CHILLS (non-serious), outcome "unknown", HEADACHE (non-serious) with onset 08May2021, outcome "recovered" (10May2021) and all described as "she received when got vaccine such as chills, a headache"; DIZZINESS (non-serious) with onset 09May2021, outcome "not recovered", described as "She says she is also experiencing dizzy spells which are not listed."; PAIN IN EXTREMITY (non-serious) with onset 08May2021, outcome "recovering", described as "She says her left arm was painful when she got the vaccine; it is still sore now but it is not as painful"; FATIGUE (non-serious) with onset 08May2021 11:45, outcome "recovering", described as "Tiredness"; PAIN (non-serious) with onset 08May2021, outcome "recovered" (10May2021), described as "Aches".  Additional information: Prior to vaccination patient had a reaction to the flu vaccine years ago. She says it was a long time ago. She does not know the lot number, NDC number, or expiration date for that flu shot. She says her reaction was that she got the full on flu for about 2 weeks.   No follow-up attempts are possible. No further information is expected.
Patient stated that he had COVID-19 a few months ago and recently had flu like sxs about 1 week ago.  Shortly after receiving the first injection of Pfizer, he began to feel lightheadedness.  VSS: 152/100 81 pulse and 98% pulse oximeter.  Offered water and snack, and after 30 minutes, resolution of lightheadedness.  Blood pressure decreased and patient was discharged to home.
Patient reports frozen shoulder and deep pain in left upper arm. Difficulty raising arm over head, started 1 week ago.
Chills, cramps, severe weakness, decreased urine output the first day despite drinking lots of H2O.  C/o "contractions inside" vagina similar to contractions that occur with orgasm:  C/o weakness, fatigue lasting 5 days.  Symptoms resolved 0 Tx.  Symptoms started that night.  Seen for knee laceration 0 previous problems with TETANUS shots.
Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient's healthcare provider, a pharmacist, at a pharmacy, recommended and/or prescribed ZOSTAVAX to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. On or about 29-MAY-2013, a pharmacist, at a pharmacy, administered the ZOSTAVAX to the patient (lot number, dosage and route of administration not provided). On or about 11-AUG-2016, the patient was treated by a physician assistant, at a health care facility for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death; aggravation of preexisting conditions and activation of latent conditions (unspecified); lost wages; loss of earnings capacity; and other losses and damages. The outcome of the events was considered to be not recovered. Causality assessment considered events to be related to the use of ZOSTAVAX. Additional information has been requested.
Fatigue, headache, body aches, fever.  I took two Advil and drank some water. Ate bland crackers
Initial unsolicited report received from a nurse on 31 July 2015. A 16-year-old female patient had received a dose of MENACTRA (batch number: U5026CA, expiry date: 24 August 2016, dose, dose in series and site of administration were not reported) intramuscularly on 22 July 2015. Patient's illness at time of vaccination reported as no and pre-existing physician diagnosed allergies, birth defects, medical conditions was reported as none. Concomitant medications were not reported. Patient was nervous about receiving vaccination. On 22 July 2015, after having it administered (few seconds after vaccination), she began to feel nauseous and dizzy, but did not tell anyone. She went into the waiting room, slumped in her chair and she fainted. Her loss of consciousness was less than one minute long. She recovered, felt better and went home with her parent. Laboratory investigations were reported as none. Corrective treatments were not reported. On 22 July 2015, the patient recovered from all the events. Upon medical review, the case was considered as serious due to important medical event: loss of consciousness. Documents held by sender: none.
exhaustion/lowered endurance; sweats lasted for 5 weeks; fever; chills; severe inflammation; asthma worsen; hot, cold; pain; increased sleep; nightmares; This is a spontaneous report received from a contactable consumer (patient) reported for herself. This 44-year-old female patient received bnt162b2 (BNT162B2), via an unspecified route of administration, administered in right arm on an unspecified date (Batch/Lot number was not reported) at single dose for COVID-19 immunisation. Patient was not pregnancy at time of vaccination. Medical history included lupus, asthma. Known allergies: latex, penicillin.  The patient's concomitant medications were not reported.  Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 14May2021 05:00 PM, the patient experienced exhaustion, lowered endurance, fever, chills, severe inflammation, asthma worsen, hot, cold, pain, increased sleep, nightmares, sweats lasted for 5 weeks. Events resulted in Doctor or other healthcare professional office/clinic visit. Treatment received for events included injection. The outcome of events was recovered/resolved with sequel.  Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19.   Information on the lot/batch number has been requested.
The case was received from health care professional on 17-Oct-2013 and on 21 March 2014 at GPV.  Initial misuse report received from a health care professional on 17 October 2013. A 71-year-old patient had received a dose of FLUZONE intradermal on an unspecified date. No adverse event was reported. List of documents held by sender: none
Severe 9/10   Right and left Achilles and low foot pain and pain on palpating-left greater than right-not relieved with Ibuprofen. This interferes with walking due to pain.Never had pain in that location  before
Mother complained of reaction after immunization given on 01/18/2005 with 35 x 34 induration, swelling, redness to right lateral thigh, mother states patient's reaction looks better since earlier AM.  Child playful with no symptoms of pain or discomfort, no fever no limitations of right leg mobility.  Instructions given to mother if reaction worsens to return or seek medical care.
No adverse event; A pharmacy staff reports that they inadvertently administered 51 doses of the monovalent vaccines/ expiration date 13Jul2022 Date(s) of administration of vaccine were 04-Aug-2022; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (A pharmacy staff reports that they inadvertently administered 51 doses of the monovalent vaccines/ expiration date 13Jul2022 Date(s) of administration of vaccine were 04-Aug-2022) and NO ADVERSE EVENT (No adverse event) in a 47-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 004M21A, 025L20A, 030L20A and 014F21A) for COVID-19 prophylaxis.     No Medical History information was reported.   On 29-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-Jan-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 08-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 04-Aug-2022, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 04-Aug-2022,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (A pharmacy staff reports that they inadvertently administered 51 doses of the monovalent vaccines/ expiration date 13Jul2022 Date(s) of administration of vaccine were 04-Aug-2022). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (A pharmacy staff reports that they inadvertently administered 51 doses of the monovalent vaccines/ expiration date 13Jul2022 Date(s) of administration of vaccine were 04-Aug-2022) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (A pharmacy staff reports that they inadvertently administered 51 doses of the monovalent vaccines/ expiration date 13Jul2022 Date(s) of administration of vaccine were 04-Aug-2022).    The concomitant medication was not reported by reporter. The treatment medication was not reported by reporter.   This case was linked to US-MODERNATX, INC.-MOD-2023-704260 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-704260:(Master case)
Case number PHEH2014US003648 is an initial spontaneous report from the pharmacist received on 21 Feb 2014. This report refers to a 60-year-old female patient who was accidentally vaccinated with MENVEO (batch number: not reported) intramuscularly on 31 Oct 2013. No adverse event reported following this medication error (inappropriate age of vaccine administration).
Rash on arm of injection. Not itchy. Slightly warm.   Pregnant. Due 9/11/21.
his 4th COVID shot last night . Had delayed immunologic response.  Allergic reaction, initial encounter -        ? Allergic reaction, subsequent encounter -
Patient received flu vaccine during flu vaccine clinic in right deltoid on 10/17/2018. The next day the patient reported shoulder soreness to administrating nurse. Administrating nurse advised patient that shoulder soreness after vaccination is common and to use comfort measures, but to follow up with primary care provider if symptoms persisted greater than 72 hours.
started 1 hour after injection: nausea, vomiting, diaphoresis, headache, blurred vision, lightheaded and dizzy, agitation. Presented to Employee Health office approximately 18 hours after injection with symptoms above. Given prescription for Phenergan 25mg suppositories.  10-20-2003 States headache, nausea/vomiting and blurred vision are cleared.  Now has generalized muscle aches and stiffness, feels balance is off, and developed small red sore rash around mouth and genital area.
The event is not confirmed to be  related to the vaccine but 3 months after I experienced prolonged (3-4 weeks) of heavy menstrual bleeding that at first I thought might be perimenopausal but the timing made me question if they might be related.  prior to that I had very light bleeding for 3 days per month.  I was bleeding through pads/tampons at 1 per hour during waking hours for 2-3 weeks resulting in anemia.  My hemoglobin was 7  GM/DL and my iron  was 11 UG/DL  Ferritin 2.4 NG/ML    All of those levels were very low vs. standard range.
LEG/FOOT CRAMPS; LEG/FOOT PAIN; This spontaneous report received from a patient concerned an elderly female. The patient's height, and weight were not reported.  The patient's concurrent conditions included leg cramps, and other pre-existing medical conditions included patient had no known allergies .The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 042A21A,  expiry: 21-JUN-2021) dose was not reported, administered on 08-APR-2021 for prophylactic vaccination. No concomitant medications were reported. On 13-APR-2021, the subject experienced leg/foot cramps. On 13-APR-2021, the subject experienced leg/foot pain. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from leg/foot cramps, and leg/foot pain on 13-APR-2021. This report was non-serious.
Patient reported experiencing a fluttering feeling  just below chest and light headed.   At 1333 patient was placed in a supine position... Vital signs were 142/84, pulse 60, Resp 18.  Patient reported feeling less light headed.  No tachy, strong radial pulse, lungs clear.  No stridor, denied numbness or tingling of lips, mouth or airway, states he had eaten that morning. At 1350 pulse 56, resp 16.  Reported feeling much better.  No light headedness, pulse and resp regular, lungs clear, no stridor or resp distress.